Liquid Biopsy Market

Peruse FMIs Liquid Biopsy Market Analysis, complete with up-to-date Growth Trends

Liquid Biopsy Market by Marker Type, Sample Type, Application Type & Region Forecast 2022 - 2032

Liquid Biopsy Market Snapshot (2022-2032)

[262 Pages Report] Global liquid biopsy market demand is anticipated to be valued at US$ 1,146 Million in 2022, forecast a CAGR of 13.49% to be valued at US$ 4,126 Million from 2022 to 2032. Growth is attributed to increasing cancer incidences and low treatment rates.

Data Points	Key Statistics
Projected Growth Rate (2022-2032)	13.49% CAGR
Expected Market Value (2022)	US$ 1,146 Million
Anticipated Forecast Value (2032)	US$ 4,126 Million

A liquid biopsy is a non-invasive procedure to surgical biopsies which helps to discover a tumor through a simple blood sample. Traces of cancer's DNA in the blood can give clues about which treatments are most likely to work for that patient.

Liquid biopsies are used for diagnosing non–small cell lung cancer (NSCLC) and screening or as a companion diagnostic for other types of cancers such as gastrointestinal, colorectal, breast, prostate, and ovarian cancer.

Cost-effectiveness and high efficacy of liquid biopsy over other diagnostic tests are chief factors responsible for market growth. Fast track approvals from regulatory bodies such as the U.S. Food and Drug Administration (FDA) for non-invasive cancer diagnosis tests will continue creating growth opportunities.

Customize this Report

Let us know your requirement to get
100% FREE customization

Customize Now

Which are Some Prominent Drivers Spearheading Liquid Biopsy Market Growth?

Government Initiatives to boost the Liquid Biopsy Market Growth

Cancer has been affecting humanity for decades, and the numbers continue to rise even with the emergence of better treatment and care. In 2020, the World Health Organization (WHO) reported nearly 10 million deaths caused due to cancer. This staggering rise in number emphasizes on the need for accurate and convenient cancer diagnostic systems for early detection.

Governments in various high cancer burden nations have pledged to assist cancer research by providing adequate funds that can aid improved outcomes. For instance, as per the National Institute of Health (NIH), the federal government has allocated US$ 119 Mn to National Cancer Institute for the fiscal year 2021.

Similarly, in 2018, India-UK Cancer Research Initiative came into effect which focused on improved and affordable approaches to cancer diagnosis and treatment. The initiative will receive investments valued at £5 Mn from the Department of Biotechnology (DBT), Ministry of Science & Technology, India, and Cancer Research UK (CRUK) each over a 5-year program.

These government-led initiatives will further promote cancer specialists across the globe to set research goals aimed at affordability, convenience, and optimal patient care in cancer treatments. Adequate funding will allow experts to develop research alliances to enable significant improvements against numerous cancer outcomes.

What are the Challenges Faced by the Liquid Biopsy Industry?

Although the liquid biopsy market has numerous end-uses, there are numerous obstacles that likely pose a challenge to market growth. The lack of skilled professionals required to operate instruments is a major factor that can restrain the growth of the market for liquid biopsy. Also, the blood Collection in liquid biopsy is a sensitive technique, and negligence in operation or lack of skill can ruin the process. Such techniques require highly qualified and trained professionals who understand the technology and mechanism.

Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

Why is North America Emerging as an Opportunistic Liquid Biopsy Market?

In terms of market share and revenue, the North American market is predicted to be the most lucrative market for liquid biopsy during the forecast period, 2022 and 2032.

One of the primary factors propelling the diagnostics industry in the region is the presence of various biotechnology and medical device firms. North America is likely to maintain its lead during the projection period due to factors such as increased spending for R&D initiatives and widespread use of new technology.

How will the Liquid Biopsy Market Expand in the U.S.?

As per FMI’s analysis, the U.S. is projected to account for 51% of the total market share in the liquid biopsy market during the assessment period. Growth prospects in the U.S. can be attributed to increasing government funding to support cancer research. Rising prevalence of cancer across the U.S. will generate high demand for highly accurate liquid biopsy services.

Wide adoption of technological developments including artificial intelligence, machine learning, and microchip-based liquid biopsy diagnostic services will lead to market expansion in the U.S.

In addition to this, the presence of major players including Biocept Inc., Janssen Global Services, and Trovagene Inc., will further lead to innovation in liquid biopsy technologies and procedures. Thereby, creating remunerative opportunities in liquid biopsy market.

Become a MarketNgage Insider

A unified Market Research Subscription Platform, built for today's disparate research needs.

Sign-Up

How Will the Growth of the European Liquid Biopsy Market Unfold?

The European liquid biopsy market is predicted to increase significantly throughout the forecast period, due to the desirable healthcare policies, along with high average per capita healthcare costs, have produced a favorable climate in the United Kingdom for the adoption of modern cancer diagnostic technology.

What is the Scope of Liquid Biopsy Market Growth in The U.K.?

As per a report by Macmillan Cancer Support, the number of cancer patients is estimated to reach 4 million by 2030. A foreseeable spike in cancer cases will underscore the need for liquid biopsy to actively diagnose patients for early treatment and care.

The presence of several well-known research institutes in the U.K. such as the University of Oxford and the National Institute of Medical Research will further lead to developments in liquid biopsy services.

These developments will provide lucrative opportunities for players operating in the market, allowing them to benefit from technological advancements for better products and services. The U.K. will account for 24% of the market share, as estimated by FMI.

Will the Asia Pacific emerge as an Attractive Liquid Biopsy Market?

The increased awareness among people about the benefits of liquid biopsy is contributing to the growth of the region as the Asia Pacific area is expected to be one of the emerging economies for cancer diagnostics. Due to the existence of a big patient pool, the availability of experienced technicians at a reduced cost, and a clear regulatory environment encouraging quicker product approvals, Asia Pacific is likely to display the strongest growth in the near future. Furthermore, the burgeoning medical tourism business in countries like China, India, and Malaysia is likely to increase demand for liquid biopsy in the region.

How will Japan Emerge as A Lucrative Market?

As per a recent report by the Japan Agency of Medical Research and Development, the country has launched ‘CIRCULATE-Japan’, a research project to analyze cancer treatments through liquid biopsy for testing circulating tumor DNA in the blood of patients suffering from colorectal cancer.

The research project is mainly launched to derive the clinical advantages of risk assessment of tumors through liquid biopsy for ‘invisible cancers’. With increasing incidence of cancer in the country, it focus on developing convenient and accurate diagnosis procedures is on the rise. These trends are anticipated to provide tailwinds to demand for liquid biopsy services as a ripple effect.

What Are the Growth Prospects for Liquid Biopsy Market in India?

Government initiatives aimed at improving cancer awareness, research, and development are anticipated to propel growth of liquid biopsy market in India, as per FMI's market survey. As revealed by the National Cancer Registry, cancer incidence in men is estimated to reach 736,575 in 2025, with 806,218 cases to be recorded in women.

Increasing number of cancer cases is anticipated to underscore the pressing need for technologically advanced liquid biopsy systems, which in turn will shape the demand outlook in the country.

Additionally, numerous budding and established biotech companies in India are focusing on research and development for early diagnosis and improvements in cancer treatment and patient care. Such developments will provide opportunities for market expansion to major global players, thereby propelling sales in India.

Startup Scenario

The new entrants in the liquid biopsy market are continually indulging in several collaborations and highly investing in research and development activities to provide more convenient solutions to industry verticals. Some of the major start-ups that are leading the development of the market are- Strand Life Sciences, DNA Labs India, and Onco Discover.

Strand Life Sciences is a clinical research and diagnostics company that combines a long track record in bioinformatics with cutting-edge laboratory assays and a vast hospital partner network to drive newer generations of patient care. Strand Life Sciences announced an agreement to acquire the India medical diagnostics business of Quest Diagnostics, the world’s leading provider of diagnostic information services.

Market Competition

Key players in the liquid biopsy market are aiming at strategic collaborations with end-users including hospitals, diagnostic centers, and cancer research institutes to strengthen their product offerings in the market. As per FMI analysis, tier-1 players will account for approximately 20-25% of the total sales.

Industry research funding and product development agreements will provide proprietary benefits to manufacturers, helping them contribute to the development of accurate diagnosis methods for various cancers. In addition, gaining patents and government approvals for new technologies will remain one of the prominent growth strategies. For instance:

In July 2021, Biocept Inc., one of the leading providers of molecular diagnostic services, received a South Korean Patent for its newly launched Primer-Switch technology. Primer-Switch technology detects mutations in circulating tumor DNA (ctDNA) using real-time PCR and related methods, identifying rare cancer biomarkers.
In July 2021, Janssen Global Services, LLC, received FDA approval for DARZALEX FASPRO in combination with pomalidomide and dexamethasone (Pd) for treating adult patients with multiple myeloma, further strengthening the company’s product offerings.

Report Scope

Report Attribute	Details
Growth Rate	CAGR of 13.49% from 2022 to 2032
Expected Market Value (2022)	US$ 1,146 Million
Anticipated Forecast Value (2032)	US$ 4,126 Million
Base Year for Estimation	2021
Historical Data	2016-2021
Forecast Period	2022-2032
Quantitative Units	Revenue in USD Billion and CAGR from 2022-2032
Report Coverage	Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis
Segments Covered	Marker Type Sample Type Application Type Region
Regions Covered	North America Latin America Western Europe Eastern Europe APEJ Japan Middle East and Africa
Key Countries Profiled	U.S Canada Mexico Brazil Germany Italy France U.K Spain Russia Poland China Japan South Korea India ASEAN Australia & New Zealand GCC South Africa
Key Companies Profiled	BIOCEPT, INC. Qiagen N.V. Trovagene, Inc Janssen Global Services, LLC MDxHealth SA Natera, Inc F. Hoffmann-La Roche Ltd Silicon Biosystems Pathway Genomics Corporation Sysmex Corporation
Customization	Available Upon Request

Key Segments Profiled in the Liquid Biopsy Industry Survey

Liquid Biopsy Market by Marker Type:

CTCs (Circulating Tumour Cells)
ctNA (Circulating tumor Nucleic Acids)
Exosomes

Liquid Biopsy Market by Sample Type:

Blood Liquid Biopsy
Urine Liquid Biopsy
Others (Plasma, Saliva, CSF) Liquid Biopsy

Liquid Biopsy Market by Application Type:

Liquid Biopsy for Lung Cancer
Liquid Biopsy for Gastrointestinal Cancer
Liquid Biopsy for Prostate Cancer
Liquid Biopsy for Breast Cancer
Liquid Biopsy for Colorectal Cancer
Liquid Biopsy for Leukemia

Liquid Biopsy Market by Region:

North America Liquid Biopsy Market
Latin America Liquid Biopsy Market
Western Europe Liquid Biopsy Market
Eastern Europe Liquid Biopsy Market
APEJ Liquid Biopsy Market
Japan Liquid Biopsy Market
Middle East and Africa Liquid Biopsy Market

Frequently Asked Questions

What is the anticipated growth of the liquid biopsy market until 2032?

FMI projects the global liquid biopsy market to expand at a 13.49% value CAGR by 2032

Which country is forecast to be the most lucrative for liquid Biopsy market growth?

US is expected to be the most opportunistic with a 51% share of the total liquid biopsy market

Which are some prominent liquid biopsy market manufacturers?

BIOCEPT, INC., Qiagen N.V., Trovagene, Inc, Janssen Global Services, LLC, MDxHealth SA, and Natera, Inc are some prominent liquid biopsy, market manufacturers.

Table of Content

1. Executive Summary

2. Assumptions and Acronyms

3. Research Methodology

4. Market Overview

    4.1. Introduction

        4.1.1. Market Definition

        4.1.2. Market Taxonomy

    4.2. Market Dynamics

        4.2.1. Drivers

        4.2.2. Restraints

        4.2.3. Opportunity

    4.3. Regional Cancer Epidemiology

    4.4. Reimbursement Scenario

    4.5. Pipeline Assessment, By Products

    4.6. Product Penetration and Pricing Impact

    4.7. Revenue Potential Liquid Biopsy

    4.8. Case Studies

5. Global Market Forecast

    5.1. Market Value (US$ Mn) Forecast

        5.1.1. Y-o-Y Growth Projections

        5.1.2. Absolute $ Opportunity

    5.2. Market Trends

    5.3. Global Market Snapshot (2015)

        5.3.1. Market Share, By Sample Type

        5.3.2. Market Share, By Disease Indication

        5.3.3. Market Share, By Marker Type

        5.3.4. Market Share, By End User

6. Global Market Analysis, By Sample Type

    6.1. Introduction

        6.1.1. Y-o-Y Growth Comparison, By Sample Type

        6.1.2. Market Share & Basis Point (BPS) Analysis, By Sample Type

    6.2. Market Forecast, By Sample Type

        6.2.1. Blood

            6.2.1.1. Absolute $ Opportunity

            6.2.1.2. Market Value (US$ Mn) Forecast

        6.2.2. Urine

            6.2.2.1. Absolute $ Opportunity

            6.2.2.2. Market Value (US$ Mn) Forecast

        6.2.3. Others (Plasma, Saliva, CSF)

            6.2.3.1. Absolute $ Opportunity

            6.2.3.2. Market Value (US$ Mn) Forecast

    6.3. Market Attractiveness Analysis, By Sample Type

7. Global Market Analysis, By Marker Type

    7.1. Introduction

        7.1.1. Y-o-Y Growth Comparison, By Marker Type

        7.1.2. Market Share & Basis Point (BPS) Analysis, By Marker Type

    7.2. Market Forecast, By Marker Type

        7.2.1. CTCs (circulating tumor cells)

            7.2.1.1. Absolute $ Opportunity

            7.2.1.2. Market Value (US$ Mn) Forecast

        7.2.2. ctNA (circulating tumor nucleic acids)

            7.2.2.1. Absolute $ Opportunity

            7.2.2.2. Market Value (US$ Mn) Forecast

        7.2.3. Exosomes

            7.2.3.1. Absolute $ Opportunity

            7.2.3.2. Market Value (US$ Mn) Forecast

    7.3. Market Attractiveness Analysis, By Marker Type

8. Global Market Analysis, By End User

    8.1. Introduction

        8.1.1. Y-o-Y Growth Comparison, By End User

        8.1.2. Market Share & Basis Point (BPS) Analysis, By End User

    8.2. Market Forecast, By End User

        8.2.1. Hospitals

            8.2.1.1. Absolute $ Opportunity

            8.2.1.2. Market Value (US$ Mn) Forecast

        8.2.2. Academic Institutes

            8.2.2.1. Absolute $ Opportunity

            8.2.2.2. Market Value (US$ Mn) Forecast

        8.2.3. Cancer Institutes

            8.2.3.1. Absolute $ Opportunity

            8.2.3.2. Market Value (US$ Mn) Forecast

        8.2.4. Diagnostic Centers

            8.2.4.1. Absolute $ Opportunity

            8.2.4.2. Market Value (US$ Mn) Forecast

    8.3. Market Attractiveness Analysis, By End User

9. Global Market Analysis, By Disease Indication

    9.1. Introduction

        9.1.1. Y-o-Y Growth Comparison, By Disease Indication

        9.1.2. Market Share & Basis Point (BPS) Analysis, By Disease Indication

    9.2. Market Forecast, By Disease Indication

        9.2.1. Lung Cancer

            9.2.1.1. Absolute $ Opportunity

            9.2.1.2. Market Value (US$ Mn) Forecast

        9.2.2. Leukemia

            9.2.2.1. Absolute $ Opportunity

            9.2.2.2. Market Value (US$ Mn) Forecast

        9.2.3. Gastrointestinal Cancer

            9.2.3.1. Absolute $ Opportunity

            9.2.3.2. Market Value (US$ Mn) Forecast

        9.2.4. Breast Cancer

            9.2.4.1. Absolute $ Opportunity

            9.2.4.2. Market Value (US$ Mn) Forecast

        9.2.5. Prostate Cancer

            9.2.5.1. Absolute $ Opportunity

            9.2.5.2. Market Value (US$ Mn) Forecast

        9.2.6. Colorectal Cancer

            9.2.6.1. Absolute $ Opportunity

            9.2.6.2. Market Value (US$ Mn) Forecast

        9.2.7. Others

            9.2.7.1. Absolute $ Opportunity

            9.2.7.2. Market Value (US$ Mn) Forecast

    9.3. Market Attractiveness Analysis, By Disease Indication

10. Global Market Analysis, By Region

    10.1. Introduction

        10.1.1. Y-o-Y Growth Projections, By Region

        10.1.2. Market Share & Basis Point (BPS) Analysis, By Region

    10.2. Market Forecast, By Region

        10.2.1. North America Market Value (US$ Mn) Forecast

        10.2.2. Latin America Market Value (US$ Mn) Forecast

        10.2.3. Western Europe Market Value (US$ Mn) Forecast

        10.2.4. Eastern Europe Market Value (US$ Mn) Forecast

        10.2.5. APEJ Market Value (US$ Mn) Forecast

        10.2.6. Japan Market Value (US$ Mn) Forecast

        10.2.7. Middle East and Africa Market Value (US$ Mn) Forecast

    10.3. Regional Attractiveness Analysis

11. North America Market Analysis

    11.1. Introduction

        11.1.1. Y-o-Y Growth Projections, By Country

        11.1.2. Market Share & Basis Point (BPS) Analysis, By Country

    11.2. Key Trends

    11.3. North America Market Forecast

        11.3.1. Market Value (US$ Mn) Forecast, By Country

            11.3.1.1. U.S. Absolute $ Opportunity

            11.3.1.2. Canada Absolute $ Opportunity

        11.3.2. Market Value (US$ Mn) Forecast, By Sample Type

            11.3.2.1. Blood

            11.3.2.2. Urine

            11.3.2.3. Others (Plasma, Saliva, CSF)

        11.3.3. Market Value (US$ Mn) Forecast, By Marker Type

            11.3.3.1. CTCs (circulating tumor cells)

            11.3.3.2. ctNA (circulating tumor nucleic acids)

            11.3.3.3. Exosomes

        11.3.4. Market Value (US$ Mn) Forecast, By End User

            11.3.4.1. Hospitals

            11.3.4.2. Academic Institutes

            11.3.4.3. Cancer Institutes

            11.3.4.4. Diagnostic Centers

        11.3.5. Market Value (US$ Mn) Forecast, By Disease Indication

            11.3.5.1. Lung Cancer

            11.3.5.2. Leukemia

            11.3.5.3. Gastrointestinal Cancer

            11.3.5.4. Breast Cancer

            11.3.5.5. Prostate Cancer

            11.3.5.6. Colorectal Cancer

            11.3.5.7. Others

    11.4. Market Attractiveness Analysis

        11.4.1. By Country

        11.4.2. By Sample Type

        11.4.3. By Disease Indication

        11.4.4. By Marker Type

        11.4.5. By End User

    11.5. Drivers & Restraints: Impact Analysis

12. Latin America Market Analysis

    12.1. Introduction

        12.1.1. Y-o-Y Growth Projections, By Country

        12.1.2. Market Share & Basis Point (BPS) Analysis, By Country

    12.2. Key Trends

    12.3. Latin America Market Forecast

        12.3.1. Market Value (US$ Mn) Forecast, By Country

            12.3.1.1. Brazil Absolute $ Opportunity

            12.3.1.2. Mexico Absolute $ Opportunity

            12.3.1.3. Rest of Latin America Absolute $ Opportunity

        12.3.2. Market Value (US$ Mn) Forecast, By Sample Type

            12.3.2.1. Blood

            12.3.2.2. Urine

            12.3.2.3. Others (Plasma, Saliva, CSF)

        12.3.3. Market Value (US$ Mn) Forecast, By Marker Type

            12.3.3.1. CTCs (circulating tumor cells)

            12.3.3.2. ctNA (circulating tumor nucleic acids)

            12.3.3.3. Exosomes

        12.3.4. Market Value (US$ Mn) Forecast, By End User

            12.3.4.1. Hospitals

            12.3.4.2. Academic Institutes

            12.3.4.3. Cancer Institutes

            12.3.4.4. Diagnostic Centers

        12.3.5. Market Value (US$ Mn) Forecast, By Disease Indication

            12.3.5.1. Lung Cancer

            12.3.5.2. Leukemia

            12.3.5.3. Gastrointestinal Cancer

            12.3.5.4. Breast Cancer

            12.3.5.5. Prostate Cancer

            12.3.5.6. Colorectal Cancer

            12.3.5.7. Others

    12.4. Market Attractiveness Analysis

        12.4.1. By Country

        12.4.2. By Sample Type

        12.4.3. By Disease Indication

        12.4.4. By Marker Type

        12.4.5. By End User

    12.5. Drivers & Restraints: Impact Analysis

13. Western Europe Market Analysis

    13.1. Introduction

        13.1.1. Y-o-Y Growth Projections, By Country

        13.1.2. Market Share & Basis Point (BPS) Analysis, By Country

    13.2. Key Trends

    13.3. Western Europe Market Forecast

        13.3.1. Market Value (US$ Mn) Forecast, By Country

            13.3.1.1. Germany Absolute $ Opportunity

            13.3.1.2. France Absolute $ Opportunity

            13.3.1.3. U.K. Absolute $ Opportunity

            13.3.1.4. Spain Absolute $ Opportunity

            13.3.1.5. Italy Absolute $ Opportunity

            13.3.1.6. Rest of Western Europe Absolute $ Opportunity

        13.3.2. Market Value (US$ Mn) Forecast, By Sample Type

            13.3.2.1. Blood

            13.3.2.2. Urine

            13.3.2.3. Others (Plasma, Saliva, CSF)

        13.3.3. Market Value (US$ Mn) Forecast, By Marker Type

            13.3.3.1. CTCs (circulating tumor cells)

            13.3.3.2. ctNA (circulating tumor nucleic acids)

            13.3.3.3. Exosomes

        13.3.4. Market Value (US$ Mn) Forecast, By End User

            13.3.4.1. Hospitals

            13.3.4.2. Academic Institutes

            13.3.4.3. Cancer Institutes

            13.3.4.4. Diagnostic Centers

        13.3.5. Market Value (US$ Mn) Forecast, By Disease Indication

            13.3.5.1. Lung Cancer

            13.3.5.2. Leukemia

            13.3.5.3. Gastrointestinal Cancer

            13.3.5.4. Breast Cancer

            13.3.5.5. Prostate Cancer

            13.3.5.6. Colorectal Cancer

            13.3.5.7. Others

    13.4. Market Attractiveness Analysis

        13.4.1. By Country

        13.4.2. By Sample Type

        13.4.3. By Disease Indication

        13.4.4. By Marker Type

        13.4.5. By End User

    13.5. Drivers & Restraints: Impact Analysis

14. Eastern Europe Market Analysis

    14.1. Introduction

        14.1.1. Y-o-Y Growth Projections, By Country

        14.1.2. Market Share & Basis Point (BPS) Analysis, By Country

    14.2. Key Trends

    14.3. Eastern Europe Market Forecast

        14.3.1. Market Value (US$ Mn) Forecast, By Country

            14.3.1.1. Russia Absolute $ Opportunity

            14.3.1.2. Poland Absolute $ Opportunity

            14.3.1.3. Rest of Eastern Europe Absolute $ Opportunity

        14.3.2. Market Value (US$ Mn) Forecast, By Sample Type

            14.3.2.1. Blood

            14.3.2.2. Urine

            14.3.2.3. Others (Plasma, Saliva, CSF)

        14.3.3. Market Value (US$ Mn) Forecast, By Marker Type

            14.3.3.1. CTCs (circulating tumor cells)

            14.3.3.2. ctNA (circulating tumor nucleic acids)

            14.3.3.3. Exosomes

        14.3.4. Market Value (US$ Mn) Forecast, By End User

            14.3.4.1. Hospitals

            14.3.4.2. Academic Institutes

            14.3.4.3. Cancer Institutes

            14.3.4.4. Diagnostic Centers

        14.3.5. Market Value (US$ Mn) Forecast, By Disease Indication

            14.3.5.1. Lung Cancer

            14.3.5.2. Leukemia

            14.3.5.3. Gastrointestinal Cancer

            14.3.5.4. Breast Cancer

            14.3.5.5. Prostate Cancer

            14.3.5.6. Colorectal Cancer

            14.3.5.7. Others

    14.4. Market Attractiveness Analysis

        14.4.1. By Country

        14.4.2. By Sample Type

        14.4.3. By Disease Indication

        14.4.4. By Marker Type

        14.4.5. By End User

15. APEJ Market Analysis

    15.1. Introduction

        15.1.1. Y-o-Y Growth Projections, By Country

        15.1.2. Market Share & Basis Point (BPS) Analysis, By Country

    15.2. Key Trends

    15.3. APEJ Market Forecast

        15.3.1. Market Value (US$ Mn) Forecast, By Country

            15.3.1.1. China Absolute $ Opportunity

            15.3.1.2. India Absolute $ Opportunity

            15.3.1.3. Australia & New Zealand Absolute $ Opportunity

            15.3.1.4. ASEAN Absolute $ Opportunity

            15.3.1.5. Rest of APEJ Absolute $ Opportunity

        15.3.2. Market Value (US$ Mn) Forecast, By Sample Type

            15.3.2.1. Blood

            15.3.2.2. Urine

            15.3.2.3. Others (Plasma, Saliva, CSF)

        15.3.3. Market Value (US$ Mn) Forecast, By Marker Type

            15.3.3.1. CTCs (circulating tumor cells)

            15.3.3.2. ctNA (circulating tumor nucleic acids)

            15.3.3.3. Exosomes

        15.3.4. Market Value (US$ Mn) Forecast, By End User

            15.3.4.1. Hospitals

            15.3.4.2. Academic Institutes

            15.3.4.3. Cancer Institutes

            15.3.4.4. Diagnostic Centers

        15.3.5. Market Value (US$ Mn) Forecast, By Disease Indication

            15.3.5.1. Lung Cancer

            15.3.5.2. Leukemia

            15.3.5.3. Gastrointestinal Cancer

            15.3.5.4. Breast Cancer

            15.3.5.5. Prostate Cancer

            15.3.5.6. Colorectal Cancer

            15.3.5.7. Others

    15.4. Market Attractiveness Analysis

        15.4.1. By Country

        15.4.2. By Sample Type

        15.4.3. By Disease Indication

        15.4.4. By Marker Type

        15.4.5. By End User

    15.5. Drivers & Restraints: Impact Analysis

16. Japan Market Analysis

    16.1. Introduction

    16.2. Key Trends

    16.3. Japan Market Forecast

        16.3.1. Market Value (US$ Mn) Forecast, By Sample Type

            16.3.1.1. Blood

            16.3.1.2. Urine

            16.3.1.3. Others (Plasma, Saliva, CSF)

        16.3.2. Market Value (US$ Mn) Forecast, By Marker Type

            16.3.2.1. CTCs (circulating tumor cells)

            16.3.2.2. ctIndication (circulating tumor nucleic acids)

            16.3.2.3. Exosomes

        16.3.3. Market Value (US$ Mn) Forecast, By End User

            16.3.3.1. Hospitals

            16.3.3.2. Academic Institutes

            16.3.3.3. Cancer Institutes

            16.3.3.4. Diagnostic Centers

        16.3.4. Market Value (US$ Mn) Forecast, By Disease Indication

            16.3.4.1. Lung Cancer

            16.3.4.2. Leukemia

            16.3.4.3. Gastrointestinal Cancer

            16.3.4.4. Metastatic Breast Cancer

            16.3.4.5. Metastatic Prostate Cancer

            16.3.4.6. Metastatic Colorectal Cancer

            16.3.4.7. Others

    16.4. Market Attractiveness Analysis

        16.4.1. By Sample Type

        16.4.2. By Disease Indication

        16.4.3. By Marker Type

        16.4.4. By End User

    16.5. Drivers & Restraints: Impact Analysis

17. Middle East and Africa Market Analysis

    17.1. Introduction

        17.1.1. Y-o-Y Growth Projections, By Country

        17.1.2. Market Share & Basis Point (BPS) Analysis, By Country

    17.2. Key Trends

    17.3. Middle East and Africa Market Forecast

        17.3.1. Market Value (US$ Mn) Forecast, By Country

            17.3.1.1. GCC Countries Absolute $ Opportunity

            17.3.1.2. South Africa Absolute $ Opportunity

            17.3.1.3. Rest of MEA Absolute $ Opportunity

        17.3.2. Market Value (US$ Mn) Forecast, By Sample Type

            17.3.2.1. Blood

            17.3.2.2. Urine

            17.3.2.3. Others (Plasma, Saliva, CSF)

        17.3.3. Market Value (US$ Mn) Forecast, By Marker Type

            17.3.3.1. CTCs (circulating tumor cells)

            17.3.3.2. ctNA (circulating tumor nucleic acids)

            17.3.3.3. Exosomes

        17.3.4. Market Value (US$ Mn) Forecast, By End User

            17.3.4.1. Hospitals

            17.3.4.2. Academic Institutes

            17.3.4.3. Cancer Institutes

            17.3.4.4. Diagnostic Centers

        17.3.5. Market Value (US$ Mn) Forecast, By Disease Indication

            17.3.5.1. Lung Cancer

            17.3.5.2. Leukemia

            17.3.5.3. Gastrointestinal Cancer

            17.3.5.4. Metastatic Breast Cancer

            17.3.5.5. Metastatic Prostate Cancer

            17.3.5.6. Metastatic Colorectal Cancer

            17.3.5.7. Others

    17.4. Market Attractiveness Analysis

        17.4.1. By Country

        17.4.2. By Sample Type

        17.4.3. By Disease Indication

        17.4.4. By Marker Type

        17.4.5. By End User

    17.5. Drivers & Restraints: Impact Analysis

18. Competition Landscape

    18.1. Competition Dashboard

    18.2. Company Profiles Inclusions

        18.2.1. Revenue

        18.2.2. Products/Brand Offerings

        18.2.3. Key developments

        18.2.4. SWOT Analysis

    18.3. Company Profiled

        18.3.1. BIOCEPT, INC.

            18.3.1.1. Revenue

            18.3.1.2. Products/Brand Offerings

            18.3.1.3. Key developments

            18.3.1.4. SWOT Analysis

        18.3.2. Qiagen N.V.

            18.3.2.1. Revenue

            18.3.2.2. Products/Brand Offerings

            18.3.2.3. Key developments

            18.3.2.4. SWOT Analysis

        18.3.3. Trovagene, Inc

            18.3.3.1. Revenue

            18.3.3.2. Products/Brand Offerings

            18.3.3.3. Key developments

            18.3.3.4. SWOT Analysis

        18.3.4. Janssen Global Services, LLC

            18.3.4.1. Revenue

            18.3.4.2. Products/Brand Offerings

            18.3.4.3. Key developments

            18.3.4.4. SWOT Analysis

        18.3.5. MDxHealth SA

            18.3.5.1. Revenue

            18.3.5.2. Products/Brand Offerings

            18.3.5.3. Key developments

            18.3.5.4. SWOT Analysis

        18.3.6. Natera, Inc

            18.3.6.1. Revenue

            18.3.6.2. Products/Brand Offerings

            18.3.6.3. Key developments

            18.3.6.4. SWOT Analysis

        18.3.7. F. Hoffmann-La Roche Ltd

            18.3.7.1. Revenue

            18.3.7.2. Products/Brand Offerings

            18.3.7.3. Key developments

            18.3.7.4. SWOT Analysis

        18.3.8. Silicon Biosystems

            18.3.8.1. Revenue

            18.3.8.2. Products/Brand Offerings

            18.3.8.3. Key developments

            18.3.8.4. SWOT Analysis

        18.3.9. Pathway Genomics Corporation

            18.3.9.1. Revenue

            18.3.9.2. Products/Brand Offerings

            18.3.9.3. Key developments

            18.3.9.4. SWOT Analysis

        18.3.10. Sysmex Corporation

            18.3.10.1. Revenue

            18.3.10.2. Products/Brand Offerings

            18.3.10.3. Key developments

            18.3.10.4. SWOT Analysis

Customize this Report

Let us know your requirement to get
100% FREE customization

Customize Now

List of Tables

Table 01: Global Market Value Forecast By Sample Type, 2022-2032

Table 02: Global Market Value Forecast By Marker Type, 2022-2032

Table 03: Global Market Value Forecast By End User, 2022-2032

Table 04: Global Market Value Forecast By Disease Indication, 2022-2032

Table 05: Global Market Value Forecast By Region, 2022-2032

Table 06: North America Market Value Forecast By Country, 2022-2032

Table 07: North America Market Value Forecast By Sample Type, 2022-2032

Table 08: North America Market Value Forecast By Marker Type, 2022-2032

Table 09: North America Market Value Forecast By End User, 2022-2032

Table 10: North America Market Value Forecast By Disease Indication, 2022-2032

Table 11: Latin America Market Value Forecast By Country, 2022-2032

Table 12: Latin America Market Value Forecast By Sample Type, 2022-2032

Table 13: Latin America Market Value Forecast By Marker Type, 2022-2032

Table 14: Latin America Market Value Forecast By End User, 2022-2032

Table 15: Latin America Market Value Forecast By Disease Indication, 2022-2032

Table 16: Western Europe Market Value Forecast By Country, 2022-2032

Table 17: Western Europe Market Value Forecast By Sample Type, 2022-2032

Table 18: Western Europe Market Value Forecast By Marker Type, 2022-2032

Table 19: Western Europe Market Value Forecast By End User, 2022-2032

Table 20: Western Europe Market Value Forecast By Disease Indication, 2022-2032

Table 21: Eastern Europe Market Value Forecast By Country, 2022-2032

Table 22: Eastern Europe Market Value Forecast By Sample Type, 2022-2032

Table 23: Eastern Europe Market Value Forecast By Marker Type, 2022-2032

Table 24: Eastern Europe Market Value Forecast By End User, 2022-2032

Table 25: Eastern Europe Market Value Forecast By Disease Indication, 2022-2032

Table 26: APEJ Market Value Forecast By Country, 2022-2032

Table 27: APEJ Market Value Forecast By Sample Type, 2022-2032

Table 28: APEJ Market Value Forecast By Marker Type, 2022-2032

Table 29: APEJ Market Value Forecast By End User, 2022-2032

Table 30: APEJ Market Value Forecast By Disease Indication, 2022-2032

Table 31: Japan Market Value Forecast By Sample Type, 2022-2032

Table 32: Japan Market Value Forecast By Marker Type, 2022-2032

Table 33: Japan Market Value Forecast By End User, 2022-2032

Table 34: Japan Market Value Forecast By Disease Indication, 2022-2032

Table 35: MEA Market Value Forecast By Country, 2022-2032

Table 36: MEA Market Value Forecast By Sample Type, 2022-2032

Table 37: MEA Market Value Forecast By Marker Type, 2022-2032

Table 38: MEA Market Value Forecast By End User, 2022-2032

Table 39: MEA Market Value Forecast By Disease Indication, 2022-2032

Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

List of Charts

Figure 01: Global Market Share Analysis (%) By Sample Type, 2022 & 2032

Figure 02: Global Market Y-o-Y growth (%) By Sample Type, 2022-2032

Figure 03: Global Market Attractiveness Analysis By Sample Type, 2022-2032

Figure 04: Global Market Value (US$ Mn) & Y-o-Y Growth (%) By Blood Sample Type Segment, 2022-2032

Figure 05: Global Market Absolute $ Opportunity (US$ Mn) By Blood Sample Type Segment, 2022-2032

Figure 06: Global Market Value (US$ Mn) & Y-o-Y Growth (%) By Urine Sample Type Segment, 2022-2032

Figure 07: Global Market Absolute $ Opportunity (US$ Mn) By Urine Sample Type Segment, 2022-2032

Figure 08: Global Market Value (US$ Mn) & Y-o-Y Growth (%) By Others (Plasma, Saliva, CSF) Sample Type Segment, 2022-2032

Figure 09: Global Market Absolute $ Opportunity (US$ Mn) By Others (Plasma, Saliva, CSF) Sample Type Segment, 2022-2032

Figure 10: Global Market Share Analysis (%) By Marker Type, 2022 & 2032

Figure 11: Global Market Y-o-Y growth (%) By Marker Type, 2022-2032

Figure 12: Global Market Attractiveness Analysis By Marker Type, 2022-2032

Figure 13: Global Market Value (US$ Mn) & Y-o-Y Growth (%) By CTCs Marker Type Segment, 2022-2032

Figure 14: Global Market Absolute $ Opportunity (US$ Mn) By CTCs Marker Type Segment, 2022-2032

Figure 15: Global Market Value (US$ Mn) & Y-o-Y Growth (%) By CtNA Marker Type Segment, 2022-2032

Figure 16: Global Market Absolute $ Opportunity (US$ Mn) By ctNA Marker Type Segment, 2022-2032

Figure 17: Global Market Value (US$ Mn) & Y-o-Y Growth (%) By Exosomes Marker Type Segment, 2022-2032

Figure 18: Global Market Absolute $ Opportunity (US$ Mn) By Exosomes Marker Type Segment, 2022-2032

Figure 19: Global Market Share Analysis (%) By End User, 2022 & 2032

Figure 20: Global Market Y-o-Y growth (%) By End User, 2022-2032

Figure 21: Global Market Attractiveness Analysis By End User, 2022-2032

Figure 22: Global Market Value (US$ Mn) & Y-o-Y Growth (%) By Hospitals End User Segment, 2022-2032

Figure 23: Global Market Absolute $ Opportunity (US$ Mn) By Hospitals End User Segment, 2022-2032

Figure 24: Global Market Value (US$ Mn) & Y-o-Y Growth (%) By Cancer Institutes End User Segment, 2022-2032

Figure 25: Global Market Absolute $ Opportunity (US$ Mn) By Cancer Institutes End User Segment, 2022-2032

Figure 26: Global Market Value (US$ Mn) & Y-o-Y Growth (%) By Academic Institutes End User Segment, 2022-2032

Figure 27: Global Market Absolute $ Opportunity (US$ Mn) By Academic Institutes End User Segment, 2022-2032

Figure 28: Global Market Value (US$ Mn) & Y-o-Y Growth (%) By Diagnostics Centers End User Segment, 2022-2032

Figure 29: Global Market Absolute $ Opportunity (US$ Mn) By Diagnostics Centers End User Segment, 2022-2032

Figure 30: Global Market Share Analysis (%) By Disease Indication, 2022 & 2032

Figure 31: Global Market Y-o-Y growth (%) By Disease Indication, 2022-2032

Figure 32: Global Market Attractiveness Analysis By Disease Indication, 2022-2032

Figure 33: Global Market Value (US$ Mn) & Y-o-Y Growth (%) By Lung Cancer Disease Indication Segment, 2022-2032

Figure 34: Global Market Absolute $ Opportunity (US$ Mn) By Lung Cancer Disease Indication Segment, 2022-2032

Figure 35: Global Market Value (US$ Mn) & Y-o-Y Growth (%) By Gastrointestinal Cancer Disease Indication Segment, 2022-2032

Figure 36: Global Market Absolute $ Opportunity (US$ Mn) By Gastrointestinal Cancer Disease Indication Segment, 2022-2032

Figure 37: Global Market Value (US$ Mn) & Y-o-Y Growth (%) By Prostate Cancer Disease Indication Segment, 2022-2032

Figure 38: Global Market Absolute $ Opportunity (US$ Mn) By Prostate Cancer Disease Indication Segment, 2022-2032

Figure 39: Global Market Value (US$ Mn) & Y-o-Y Growth (%) By Breast Cancer Disease Indication Segment, 2022-2032

Figure 40: Global Market Absolute $ Opportunity (US$ Mn) By Breast Cancer Disease Indication Segment, 2022-2032

Figure 41: Global Market Value (US$ Mn) & Y-o-Y Growth (%) By Colorectal Cancer Disease Indication Segment, 2022-2032

Figure 42: Global Market Absolute $ Opportunity (US$ Mn) By Colorectal Cancer Disease Indication Segment, 2022-2032

Figure 43: Global Market Value (US$ Mn) & Y-o-Y Growth (%) By Leukemia Disease Indication Segment, 2022-2032

Figure 44: Global Market Absolute $ Opportunity (US$ Mn) By Leukemia Disease Indication Segment, 2022-2032

Figure 45: Global Market Value (US$ Mn) & Y-o-Y Growth (%) By Others Cancer Disease Indication Segment, 2022-2032

Figure 46: Global Market Absolute $ Opportunity (US$ Mn) By Others Cancer Disease Indication Segment, 2022-2032

Figure 47: Global Market Share Analysis (%) By Region, 2022 & 2032

Figure 48: Global Market Y-o-Y growth (%) By Region, 2022-2032

Figure 49: Global Market Attractiveness Analysis By Region, 2022-2032

Figure 50: North America Market Value (US$ Mn) & Y-o-Y Growth (%), 2022-2032

Figure 51: North America Market Absolute $ Opportunity (US$ Mn), 2022-2032

Figure 53: Latin America Market Absolute $ Opportunity (US$ Mn), 2022-2032

Figure 54: Western Europe Market Value (US$ Mn) & Y-o-Y Growth (%), 2022-2032

Figure 55: Western Europe Market Absolute $ Opportunity (US$ Mn), 2022-2032

Figure 56: Eastern Europe Market Value (US$ Mn) & Y-o-Y Growth (%), 2022-2032

Figure 57: Eastern Europe Market Absolute $ Opportunity (US$ Mn), 2022-2032

Figure 58: APEJ Market Value (US$ Mn) & Y-o-Y Growth (%), 2022-2032

Figure 59: APEJ Market Absolute $ Opportunity (US$ Mn), 2022-2032

Figure 60: Japan Market Value (US$ Mn) & Y-o-Y Growth (%), 2022-2032

Figure 61: Japan Market Absolute $ Opportunity (US$ Mn), 2022-2032

Figure 62: MEA Market Value (US$ Mn) & Y-o-Y Growth (%), 2022-2032

Figure 63: MEA Market Absolute $ Opportunity (US$ Mn), 2022-2032

Figure 64: North America Market Share Analysis (%) By Country, 2022 & 2032

Figure 65: North America Market Y-o-Y growth (%) By Country, 2022-2032

Figure 66: North America Market Attractiveness Analysis By Country, 2022-2032

Figure 67: The U.S. Market Value (US$ Mn) & Y-o-Y Growth (%), 2022-2032

Figure 68: The U.S. Market Absolute $ Opportunity (US$ Mn), 2022-2032

Figure 69: Canada Market Value (US$ Mn) & Y-o-Y Growth (%), 2022-2032

Figure 70: Canada Market Absolute $ Opportunity (US$ Mn), 2022-2032

Figure 71: North America Market Attractiveness Analysis By Marker Type, 2022-2032

Figure 72: North America Market Attractiveness Analysis By End User, 2022-2032

Figure 73: North America Market Attractiveness Analysis By Sample Type, 2022-2032

Figure 74: North America Market Attractiveness Analysis By Disease Indication, 2022-2032

Figure 75: Latin America Market Share Analysis (%) By Country, 2022 & 2032

Figure 76: Latin America Market Y-o-Y growth (%) By Country, 2022-2032

Figure 77: Latin America Market Attractiveness Analysis By Country, 2022-2032

Figure 78: Brazil Market Value (US$ Mn) & Y-o-Y Growth (%), 2022-2032

Figure 79: Brazil Market Absolute $ Opportunity (US$ Mn), 2022-2032

Figure 80: Mexico Market Value (US$ Mn) & Y-o-Y Growth (%), 2022-2032

Figure 81: Mexico Market Absolute $ Opportunity (US$ Mn), 2022-2032

Figure 82: Rest of Latin America Market Value (US$ Mn) & Y-o-Y Growth (%), 2022-2032

Figure 83: Rest of Latin America Market Absolute $ Opportunity (US$ Mn), 2022-2032

Figure 84: Latin America Market Attractiveness Analysis By Marker Type, 2022-2032

Figure 85: Latin America Market Attractiveness Analysis By End User, 2022-2032

Figure 86: Latin America Market Attractiveness Analysis By Sample Type, 2022-2032

Figure 87: Latin America Market Attractiveness Analysis By Disease Indication, 2022-2032

Figure 90: Western Europe Market Share Analysis (%) By Country, 2022 & 2032

Figure 91: Western Europe Market Y-o-Y growth (%) By Country, 2022-2032

Figure 92: Western Europe Market Attractiveness Analysis By Country, 2022-2032

Figure 93: The U.K Market Value (US$ Mn) & Y-o-Y Growth (%), 2022-2032

Figure 94: The U.K Market Absolute $ Opportunity (US$ Mn), 2022-2032

Figure 95: Germany Market Value (US$ Mn) & Y-o-Y Growth (%), 2022-2032

Figure 96: Germany Market Absolute $ Opportunity (US$ Mn), 2022-2032

Figure 97: France Market Value (US$ Mn) & Y-o-Y Growth (%), 2022-2032

Figure 98: France Market Absolute $ Opportunity (US$ Mn), 2022-2032

Figure 99: Spain the market Value (US$ Mn) & Y-o-Y Growth (%), 2022-2032

Figure 100: Spain the market Absolute $ Opportunity (US$ Mn), 2022-2032

Figure 101: Italy Market Value (US$ Mn) & Y-o-Y Growth (%), 2022-2032

Figure 102: Italy Market Absolute $ Opportunity (US$ Mn), 2022-2032

Figure 103: NORDIC Market Value (US$ Mn) & Y-o-Y Growth (%), 2022-2032

Figure 104: NORDIC Market Absolute $ Opportunity (US$ Mn), 2022-2032

Figure 105: BENELUX Market Value (US$ Mn) & Y-o-Y Growth (%), 2022-2032

Figure 106: BENELUX Market Absolute $ Opportunity (US$ Mn), 2022-2032

Figure 107: Rest of Western Europe Market Value (US$ Mn) & Y-o-Y Growth (%), 2022-2032

Figure 108: Rest of Western Europe Market Absolute $ Opportunity (US$ Mn), 2022-2032

Figure 109: Western Europe Market Attractiveness Analysis By Marker Type, 2022-2032

Figure 110: Western Europe Market Attractiveness Analysis By End User, 2022-2032

Figure 111: Western Europe Market Attractiveness Analysis By Sample Type, 2022-2032

Figure 112: Western Europe Market Attractiveness Analysis By Disease Indication, 2022-2032

Figure 113: Eastern Europe Market Share Analysis (%) By Country, 2022 & 2032

Figure 114: Eastern Europe Market Y-o-Y growth (%) By Country, 2022-2032

Figure 115: Eastern Europe Market Attractiveness Analysis By Country, 2022-2032

Figure 116: Russia Market Value (US$ Mn) & Y-o-Y Growth (%), 2022-2032

Figure 117: Russia Market Absolute $ Opportunity (US$ Mn), 2022-2032

Figure 118: Poland Market Value (US$ Mn) & Y-o-Y Growth (%), 2022-2032

Figure 119: Poland Market Absolute $ Opportunity (US$ Mn), 2022-2032

Figure 120: Rest of Eastern Europe Market Value (US$ Mn) & Y-o-Y Growth (%), 2022-2032

Figure 121: Rest of Eastern Europe Market Absolute $ Opportunity (US$ Mn), 2022-2032

Figure 122: Eastern Europe Market Attractiveness Analysis By Marker Type, 2022-2032

Figure 123: Eastern Europe Market Attractiveness Analysis By End User, 2022-2032

Figure 124: Eastern Europe Market Attractiveness Analysis By Sample Type, 2022-2032

Figure 125: Eastern Europe Market Attractiveness Analysis By Disease Indication, 2022-2032

Figure 126: APEJ Market Share Analysis (%) By Country, 2022 & 2032

Figure 127: APEJ Market Y-o-Y growth (%) By Country, 2022-2032

Figure 128: APEJ Market Attractiveness Analysis By Country, 2022-2032

Figure 129: China Market Value (US$ Mn) & Y-o-Y Growth (%), 2022-2032

Figure 130: China Market Absolute $ Opportunity (US$ Mn), 2022-2032

Figure 131: India Market Value (US$ Mn) & Y-o-Y Growth (%), 2022-2032

Figure 132: India Market Absolute $ Opportunity (US$ Mn), 2022-2032

Figure 133: Australia & New Zealand Market Value (US$ Mn) & Y-o-Y Growth (%), 2022-2032

Figure 134: Australia & New Zealand Market Absolute $ Opportunity (US$ Mn), 2022-2032

Figure 135: ASEAN Market Value (US$ Mn) & Y-o-Y Growth (%), 2022-2032

Figure 136: ASEAN Market Absolute $ Opportunity (US$ Mn), 2022-2032

Figure 137: Rest of APEJ Market Value (US$ Mn) & Y-o-Y Growth (%), 2022-2032

Figure 138: Rest of APEJ Market Absolute $ Opportunity (US$ Mn), 2022-2032

Figure 139: APEJ Market Attractiveness Analysis By Marker Type, 2022-2032

Figure 140: APEJ Market Attractiveness Analysis By End User, 2022-2032

Figure 141: APEJ Market Attractiveness Analysis By Sample Type, 2022-2032

Figure 142: APEJ Market Attractiveness Analysis By Disease Indication, 2022-2032

Figure 145: Japan Market Attractiveness Analysis By Sample Type, 2022-2032

Figure 146: Japan Market Attractiveness Analysis By Disease Indication, 2022-2032

Figure 143: Japan Market Attractiveness Analysis By Marker Type, 2022-2032

Figure 144: Japan Market Attractiveness Analysis By End User, 2022-2032

Figure 147: MEA Market Share Analysis (%) By Country, 2022 & 2032

Figure 148: MEA Market Y-o-Y growth (%) By Country, 2022-2032

Figure 149: MEA Market Attractiveness Analysis By Country, 2022-2032

Figure 150: GCC Countries Market Value (US$ Mn) & Y-o-Y Growth (%), 2022-2032

Figure 151: GCC Countries Market Absolute $ Opportunity (US$ Mn), 2022-2032

Figure 152: South Africa Market Value (US$ Mn) & Y-o-Y Growth (%), 2022-2032

Figure 153: South Africa Market Absolute $ Opportunity (US$ Mn), 2022-2032

Figure 154: Rest of MEA Market Value (US$ Mn) & Y-o-Y Growth (%), 2022-2032

Figure 155: Rest of MEA Market Absolute $ Opportunity (US$ Mn), 2022-2032

Figure 156: MEA Market Attractiveness Analysis By Marker Type, 2022-2032

Figure 157: MEA Market Attractiveness Analysis By End User, 2022-2032

Figure 158: MEA Market Attractiveness Analysis By Sample Type, 2022-2032

Figure 159: MEA Market Attractiveness Analysis By Disease Indication, 2022-2032